Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| PACIRA (NASDAQ: PCRX) | Delayed: 36.36 +0.02 (0.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.34 | 52 Week High | $80.25 | |||
| Open | $36.33 | 52 Week Low | $30.25 | |||
| Day High | $36.38 | P/E | N/A | |||
| Day Low | $36.33 | EPS | $-2.08 | |||
| Volume | 204,448 | |||||
